RIGEL PHARMACEUTICALS, INC. Amortization of Intangible Assets
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Amortization of Intangible Assets of $600.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-05-05
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $600.00K, a 0.00% change year-over-year.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $600.00K, a 20.00% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $600.00K, a 0.00% change year-over-year.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-06-30 was $600.00K, a 0.00% change year-over-year.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $2.40M, a 14.29% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $2.10M, a 90.91% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $1.10M, a 1000.00% increase from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $100.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-03-31 | $600.00K 10-Q · filed 2026-05-05 | $1.20M derived: sum of 2 quarters · filed 2026-05-05 | $1.80M derived: sum of 3 quarters · filed 2026-05-05 | $2.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.20M derived: sum of 2 quarters · filed 2026-03-03 | $1.80M derived: sum of 3 quarters · filed 2026-03-03 | $2.40M 10-K · filed 2026-03-03 |
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-04 | $1.20M derived: sum of 2 quarters · filed 2025-11-04 | $1.80M 10-Q · filed 2025-11-04 | $2.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $600.00K 10-Q · filed 2025-08-05 | $1.20M 10-Q · filed 2025-08-05 | $1.70M derived: sum of 3 quarters · filed 2026-05-05 | $2.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-05 | $1.10M derived: sum of 2 quarters · filed 2026-05-05 | $1.70M derived: sum of 3 quarters · filed 2026-05-05 | $2.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.10M derived: sum of 2 quarters · filed 2026-03-03 | $1.70M derived: sum of 3 quarters · filed 2026-03-03 | $2.10M 10-K · filed 2026-03-03 |
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-04 | $1.20M derived: sum of 2 quarters · filed 2025-11-04 | $1.60M 10-Q · filed 2025-11-04 | $1.90M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-05 | $1.00M 10-Q · filed 2025-08-05 | $1.30M derived: sum of 3 quarters · filed 2026-03-03 | $1.60M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $400.00K 10-Q · filed 2025-05-06 | $700.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.00M derived: sum of 3 quarters · filed 2026-03-03 | $1.30M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $600.00K derived: sum of 2 quarters · filed 2026-03-03 | $900.00K derived: sum of 3 quarters · filed 2026-03-03 | $1.10M 10-K · filed 2026-03-03 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-07 | $600.00K derived: sum of 2 quarters · filed 2024-11-07 | $800.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-06 | $500.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $100.00K 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |